News | Heart Valve Technology | August 12, 2020

National Survey Of Heart Valve Patients Shows Importance Of Seeking Treatment Early

New awareness campaign empowers patients to proactively manage treatment decisions as fears of hospital visits increase during COVID-19

National Survey Of Heart Valve Patients Shows Importance Of Seeking Treatment Early

August 12, 2020 — A national survey conducted by the patient advocacy group Heart-Valve-Surgery.com with support by Medtronic, found that nearly half (49 percent) of heart valve patients said returning to active living is a key factor in their treatment decision. The survey of more than 3,400 heart valve patients and caregivers uncovered real-world insights around managing heart valve disease, from diagnosis through treatment and beyond. The survey findings help kick off a new Active Living Awareness Initiative.

The initiative comes at a time when heart valve disease impacts more than five million Americans, including 1.5 million with aortic stenosis (AS). Considered to be one of the most common and severe forms of heart valve disease, AS occurs when the aortic valve narrows, preventing the leaflets from properly opening and closing, and diminishing blood flow between the heart and the rest of the body. In fact, 50 percent of patients with AS who go untreated do not survive more than two years after the onset of symptoms.

Despite the prevalence and severity of AS, the American Heart Association (AHA) warns that the COVID-19 pandemic has put health care on hold for many individuals leading to heart health emergencies.

For patients who are candidates, minimally invasive procedures, such as transcatheter aortic valve replacement (TAVR), generally require less time in the hospital with faster procedure times, and may result in a quicker recovery.

"From my personal experience as a heart valve patient and in helping millions of patients fight heart valve disease, I know how critical it is to be an informed patient and seek treatment before the disease becomes fatal," said Adam Pick, patient advocate and founder of Heart-Valve-Surgery.com. "Now more than ever, patients should feel empowered to take a meaningful and decisive role in their treatment decision-making process. We learned through this survey that many patients want to be active again – whether that means going back to work, spending more time with family and friends, or simply feeling well enough to walk up the stairs or to the mailbox."

The survey found that most respondents (90 percent) who identified as heart valve patients are more influenced by conversations with their doctor when making treatment decisions, while other top factors included conducting their own online research (55 percent) and having conversations with family or friends (28 percent). As the option of TAVR expands to new patient populations, a shared decision-making approach may be the best option for all patients considering aortic valve replacement, according to a March 2020 paper published in the Journal of the American College of Cardiology (JACC).[1]

"With the majority of heart valve patients reporting conversations with their doctors as the most important factor in their treatment choice, the importance in seeking treatment early and having an informed dialogue with their physicians, cannot be overstated," said Kendra Grubb, M.D., surgical director with the Structural Heart and Valve Center at Emory Healthcare in Atlanta. "These conditions need to be taken seriously early on, and we want patients to know that meeting with their doctor and considering all the factors is a vital first step in getting healthy again."

Additional key findings from the survey include:

   • More than one-fourth of heart valve patients (27 percent) wished they sought treatment earlier.
   • Reputation of the hospital or doctor (85 percent) and surgery success rate (62 percent) led the way in patient decision making for heart valve patients.
   • The majority (87 percent) of patients with aortic stenosis consider the disease a condition that worsens over time
   • The majority of respondents who had a heart valve procedure reported exercising as the number one activity they are able to enjoy again (82 percent), followed by working full- or part-time (46 percent) and travelling (45 percent).
   • Patients who had a heart valve procedure reported the top benefits to minimally invasive procedures as less time in the hospital (56 percent) and a faster return to an active lifestyle (55 percent). The majority of patients who received TAVR (98 percent) reported being satisfied with TAVR as a treatment option.

The Active Living Awareness Initiative aims to educate on the importance of early treatment and diagnosis for heart valve disease, including AS. Key findings from the Active Living survey are available via an interactive microsite at Heart-Valve-Surgery.com. The microsite provides visitors video content about AS and its treatment, educational references including a Physician Finder, and free downloads including a checklist of "Aortic Stenosis: 5 Questions to Consider Before Treatment." 

Explore the Active Living microsite.

 

About the Heart Valve Surgery Survey

These results are based on an online survey issued to the Heart-Valve-Surgery.com community, the world's largest educational resource and community of heart valve patients. More than 3,400 responses were received from heart valve patients and caregivers. The respondents were a 50/50 male female split with 72 percent over the age of 60 and 91 percent over the age of 50. Of the respondents, 94 percent identified as heart valve patients, 53 percent identified as aortic stenosis patients.

About Adam Pick and Heart-Valve-Surgery.com

Adam Pick is a heart valve patient and author of The Patient's Guide To Heart Valve Surgery. In 2006, Adam founded Heart-Valve-Surgery.com to educate and to empower patients from diagnosis through recovery. This award-winning website, which is sponsored by over 40 cardiac centers, has helped more than 10 million people fight heart valve disease. Adam has been featured by the American Heart Association and is currently followed by over 300,000 people across social media.

 
Reference:

1. Megan Coylewright, John K. Forrest, James M. McCabe and Tamim M. Nazif. TAVR in Low-Risk Patients. FDA Approval, the New NCD, and Shared Decision-Making. Journal of the American College of Cardiology. Volume 75, Issue 10, March 2020. DOI: 10.1016/j.jacc.2019.12.057.

 

Related Content

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, mor
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp.
The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. #TCT #TCT2020 #TCTconnect

The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. 

News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart
The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020. #TCT #TCT2020 #TCTconnect

The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020.

Feature | Heart Valve Technology | October 15, 2020
October 15, 2020 – The SCOPE II trial comparing the Boston Scientific Acurate neo vs.
An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture. #TCT2020 #TCTconnect

An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture.

News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The...
Medtronic is starting a randomized, head-to-head study comparing the Medtronic CoreValve Evolut Pro and Pro+TAVR Systems against the balloon-expandable Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valvestwo transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS). 

Medtronic is starting a randomized, head-to-head study comparing the Medtronic CoreValve Evolut Pro and Pro+TAVR Systems against the balloon-expandable Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valvestwo transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS). 

News | Heart Valve Technology | October 14, 2020
October 14, 2020 — Medtronic announced it is starting a randomized, head-to-head study comparing two transcatheter ao
The Cardiac Dimensions Carillon Mitral Contour System, a transcatheter device used to treat functional mitral regurgitation (FMR) in patients with heart failure.
News | Heart Valve Technology | October 02, 2020
October 2, 2020 — Cardiac Dimensions announced the company has closed a $17.5 million Series C financing that will be
Boston Scientific launched the Acurate neo2 transcatheter aortic valve replacement (TAVR) system in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original Acurate neo platform. Compared to the previous generation device, the Acurate neo2 valve system also has an expanded indication for patients with aortic stenosis. #TAVR #TAVI
News | Heart Valve Technology | September 29, 2020
September 29, 2020 — Boston Scientific launched the...